Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell genomics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments and consumables, including IFCs, assays, and reagents to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000
Debt
Debt-to-Equity Ratio4.79
Current Ratio2.05
Quick Ratio1.64
Price-To-Earnings
Trailing P/E Ratio-6.02
Forward P/E Ratio-6.87
P/E GrowthN/A
Sales & Book Value
Annual Sales$101.94 million
Price / Sales2.61
Cash FlowN/A
Price / CashN/A
Book Value$0.80 per share
Price / Book8.50
Profitability
EPS (Most Recent Fiscal Year)($1.19)
Net Income$-60,530,000.00
Net Margins-53.65%
Return on Equity-104.75%
Return on Assets-14.50%
Miscellaneous
Employees505
Outstanding Shares39,160,000
Market Cap$280.80 million
Fluidigm (NASDAQ:FLDM) Frequently Asked Questions
What is Fluidigm's stock symbol?
Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."
How were Fluidigm's earnings last quarter?
Fluidigm Co. (NASDAQ:FLDM) released its quarterly earnings results on Thursday, August, 2nd. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.03. The medical research company had revenue of $26.43 million for the quarter, compared to the consensus estimate of $26.30 million. Fluidigm had a negative return on equity of 104.75% and a negative net margin of 53.65%. View Fluidigm's Earnings History.
When is Fluidigm's next earnings date?
What price target have analysts set for FLDM?
1 analysts have issued 12-month price objectives for Fluidigm's stock. Their predictions range from $6.10 to $6.10. On average, they expect Fluidigm's share price to reach $6.10 in the next twelve months. This suggests that the stock has a possible downside of 12.9%. View Analyst Price Targets for Fluidigm.
What is the consensus analysts' recommendation for Fluidigm?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Fluidigm.
Who are some of Fluidigm's key competitors?
Who are Fluidigm's key executives?
Fluidigm's management team includes the folowing people:
- Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 45)
- Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 62)
- Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 44)
- Mr. Steven C. McPhail, Chief Commercial Officer (Age 64)
- Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 59)
Has Fluidigm been receiving favorable news coverage?
Media coverage about FLDM stock has trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fluidigm earned a news impact score of 0.13 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.45 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Fluidigm.
Who are Fluidigm's major shareholders?
Fluidigm's stock is owned by a number of of institutional and retail investors. Top institutional investors include Levin Capital Strategies L.P. (26.23%), Russell Investments Group Ltd. (11.29%), BlackRock Inc. (5.14%), Renaissance Technologies LLC (2.73%), Healthcare Value Capital LLC (1.16%) and Bank of New York Mellon Corp (1.11%). Company insiders that own Fluidigm stock include Evan/ Fa Jones, Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Institutional Ownership Trends for Fluidigm.
Which institutional investors are selling Fluidigm stock?
FLDM stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., BlackRock Inc., Millennium Management LLC, Schwab Charles Investment Management Inc. and Rhumbline Advisers. View Insider Buying and Selling for Fluidigm.
Which institutional investors are buying Fluidigm stock?
FLDM stock was purchased by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., Acadian Asset Management LLC, Renaissance Technologies LLC, Los Angeles Capital Management & Equity Research Inc., Paloma Partners Management Co, Healthcare Value Capital LLC, Bank of New York Mellon Corp and Jennison Associates LLC. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Samuel D Colella, Stephen Christopher Linthwaite and Steven Mcphail. View Insider Buying and Selling for Fluidigm.
How do I buy shares of Fluidigm?
Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fluidigm's stock price today?
One share of FLDM stock can currently be purchased for approximately $7.00.
How big of a company is Fluidigm?
Fluidigm has a market capitalization of $280.80 million and generates $101.94 million in revenue each year. The medical research company earns $-60,530,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fluidigm employs 505 workers across the globe.
How can I contact Fluidigm?
Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000.
MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
